Brief: Catalyst Pharmaceuticals Says Drug To Treat Rare Muscular Dystrophy Now Commercially Available In The US

Catalyst Pharmaceuticals

13/03/2024 11:58

March 13 (Reuters) - Catalyst Pharmaceuticals Inc
 CPRX.O :
    * CATALYST PHARMACEUTICALS ANNOUNCES AGAMREE® NOW
COMMERCIALLY
AVAILABLE IN THE U.S. FOR THE TREATMENT OF DUCHENNE MUSCULAR
DYSTROPHY (DMD)

Source text for Eikon:  ID:nGNX7dDDkz 
Further company coverage:  CPRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))